With the promising results from the BDNF expressing MSCs [40] and lentiviral safety [41], the California Institute for Regenerative Medicine (CIRM) granted the University of California at Davis to take lentivirally engineered MSCs to overexpress BDNF to the clinic, with the goal of creating an FDA-approved cellular therapy for HD. This evidence concerns the gene BDNF and Huntington disease.